PriceTargets.com logo

Oncopeptides AB (publ) - ONPPF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.27 As of 11/15/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for ONPPF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oncopeptides AB (publ) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONPPF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONPPF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Oncopeptides AB (publ) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.27.

This chart shows the closing price for ONPPF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Oncopeptides AB (publ). This rating has held steady since July 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/14/2023DNB MarketsDowngradeBuy ➝ Hold
10/25/2021DNB MarketsDowngradeBuy ➝ Sell
7/29/2021HC WainwrightReiterated RatingSell
7/13/2021HC WainwrightDowngradeBuy ➝ Sell
(Data available from 11/17/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

Oncopeptides AB (publ)

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Read More

Today's Range

Now: $0.27
Low: $0.27
High: $0.27

50 Day Range

MA: $0.27
Low: $0.27
High: $0.27

52 Week Range

Now: $0.27
Low: $0.27
High: $0.27

Volume

N/A

Average Volume

2,250 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Oncopeptides AB (publ)?

The following sell-side analysts have issued reports on Oncopeptides AB (publ) in the last year:
View the latest analyst ratings for ONPPF.

What is the current price target for Oncopeptides AB (publ)?

0 Wall Street analysts have set twelve-month price targets for Oncopeptides AB (publ) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Oncopeptides AB (publ) in the next year.
View the latest price targets for ONPPF.

What is the current consensus analyst rating for Oncopeptides AB (publ)?

Oncopeptides AB (publ) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ONPPF.

What other companies compete with Oncopeptides AB (publ)?

Other companies that are similar to Oncopeptides AB (publ) include 180 Life Sciences, 3SBio, 60 Degrees Pharmaceuticals, Abcam and Adocia. Learn More about companies similar to Oncopeptides AB (publ).

How do I contact Oncopeptides AB (publ)'s investor relations team?

Oncopeptides AB (publ)'s physical mailing address is Vastra Tradgardsgatan 15, Stockholm 111 53, Sweden. The company's listed phone number is 46 86 15 20 40. The official website for Oncopeptides AB (publ) is www.oncopeptides.se. Learn More about contacing Oncopeptides AB (publ) investor relations.